Brought to you by 
Cubist buys Optimer for $524mm in cash, plus CVRs
24 Aug 2020
Executive Summary
Acute care firm Cubist Pharmaceuticals Inc. is acquiring all the outstanding common stock of public antibiotics developer Optimer Pharmaceutical Inc. for $10.75 per share (a 24% discount) in cash, or a total of $523.7mm. The transaction also includes earn-outs in the form of contingent value rights (CVRs), which would give Optimer shareholders up to $5.00 for each share they own--a total of $243.6mm--if certain net sales of Dificid (fidaxomicin) are met.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist buys Optimer for $524mm in cash, plus CVRs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice